NEW YORK (GenomeWeb News) – Waters today said that revenues in the third quarter dropped about 1 percent year over year as foreign currency translation tamped down sales by 3 percent.

For the three months ended Sept. 29, Waters reeled in $450.0 million in total revenue, down from $454.5 million a year ago and short of consensus Wall Street estimates of $451.1 million.

According to Chairman, President, and CEO Douglas Berthiaume, Waters saw stable pharmaceutical demand as well as strong sales in Asia allowing the company to grow organically during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.